Join A Study
The only way we will find a cure for Parkinson’s disease (PD) is through research. Your participation in research is critical to finding new treatments and improving life for the 10 million people living with Parkinson’s around the world.
Explore the different opportunities to get involved with Parkinson’s research.
Parkinson’s Foundation Studies
PD GENEration: Mapping the Future of Parkinson’s Disease
This national initiative offered by the Parkinson’s Foundation provides genetic testing for clinically relevant Parkinson's-related genes and genetic counseling at no cost for people with Parkinson’s. Participation can be either in-person or from home.
Parkinson’s Foundation Surveys
Through this initiative, we aim to advance Parkinson’s care through understanding the experiences of people living with this disease, care partners and healthcare workers —and widely sharing those experiences with the PD community.
Parkinson’s Foundation Collaborative Studies
TOPAZ Trial
People with Parkinson's have a higher risk of fractures. Help us find a solution. Through this NIH-funded study in collaboration with the California Pacific Medical Center Research Institute, the TOPAZ study will test if a medicine called zoledronate can prevent fractures in people with PD. A team of doctors who are experts in bone health and PD are leading the study.
PERSEVERE Study
PERSEVERE is an NIH-funded study in collaboration with Dr. Jori Fleischer at Rush University. This study is testing an educational program for care partners of people with Parkinson’s Disease with cognitive impairment, Parkinson’s Disease Dementia, Dementia with Lewy Bodies, or Lewy Body Dementia. PERSEVERE will test whether a disease-specific, caregiver-centered educational program improves caregiver knowledge, confidence, strain, and health outcomes – and whether it helps people living with Parkinson’s Disease Dementia, Dementia with Lewy Bodies, or Lewy Body Dementia, too.
Parkinson’s Foundation Industry Consortium Member Studies
Consortium members are companies engaged with the Foundation in support of our mission to end PD. Trials listed here are not endorsed by the Parkinson’s Foundation. Read more about corporate sponsorship and our consortium here.
NEULARK Trial
The NEULARK Trial, sponsored by Neuron23, is testing a once-daily oral investigational drug called NEU-411 in people between the ages of 50 to 80 who have been diagnosed with Parkinson’s disease and who have not yet received dopamine medications. This innovative trial will test whether NEU-411 can slow disease progression in a newly defined population of patients with Parkinson’s disease who match a specific genetic profile based on a blood test.
PROPEL Trial
The PROPEL Study, sponsored by Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, is testing a one-time gene therapy investigational drug called PR001 in people between 35 and 80 who have been diagnosed with Parkinson's disease and carry a mutation in their GBA1 gene. Mutations in GBA1 increase the risk of developing Parkinson’s disease and are the most common genetic cause of Parkinson’s disease. PR001, which provides a healthy copy of GBA1 gene by one-time delivery, is being developed as a potentially disease-modifying treatment for PD-GBA.
Sunrise-PD Trial
The Sunrise-PD clinical study, sponsored by the pharmaceutical company BioVie Inc, is testing the oral investigational treatment bezisterim to determine whether bezisterim can improve motor symptoms of Parkinson’s in individuals 45 to 80 years old who are ready to begin but have not started treatment yet. Bezisterim is believed to act by reducing inflammation in the brain that may contribute to symptoms of Parkinson’s disease.
Industry Consortium Partners
Thank you to our industry consortium partners for aligning with the PD GENEration study for the betterment of people with PD.
Non-Profit Consortium Partners
SPARK NS
Founded in 2023, SPARK NS is an independent non-profit translational research organization dedicated to efficiently advancing promising neuroscience discoveries from the lab to the clinic. SPARK NS offers two-year, immersive translational research programs that provide funding, education, mentorship, and networking opportunities to academic principal investigators (PIs) with promising therapeutic discoveries. The programs are designed to close gaps in knowledge and know-how and eliminate barriers that slow or prevent promising discoveries from directly benefiting patients.
Become a Research Advocate
Help us make Parkinson’s research more efficient and effective. Our trained research advocates partner alongside scientists, industry and government on critical PD research studies.
Find more clinical studies and trials for people with PD
- ClinicalTrials.gov contains a complete list of PD-related trials.
Explore precision medicine trials such as GBA and LRKK2, designed for people with a confirmed genetic link to Parkinson’s, as tested in the PD GENEration study.
Additional studies and trials:
Join the Fight Against Parkinson's
Support ground-breaking research, care and community outreach
Related Materials
Related Blog Posts
The Ins and Outs of Participating in Parkinson’s Research
Parkinson’s Foundation Research Advocates Influence Parkinson’s Funding
